A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.


Updates from The Motley Fool

Latest updates on Geron from Fool.com.  The Fool has written over 200 articles on Geron.
4 Top Stocks Under $5

These small stocks could have a big impact on your portfolio.



Stock Performance

View Interactive GERN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Geron.
Current Price: $2.92
Prev Close: $2.94
Open: $2.97
Bid: $2.90
Ask: $2.91
Day's Range: $2.88 - $2.99
52wk Range: $1.81 - $3.15
Volume: 860,656
Avg Vol 1,626,731
Market Cap: $464M
P/E (ttm): -16.33
EPS (ttm): ($0.18)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Geron.
CAPS Rating 2 out of 5
 
646 Outperform
61 Underperform
CAPS All Stars
 
88 Outperform
19 Underperform

How do you think Geron will perform against the market?



You pick for Geron is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John A. Scarlett, CEO

73% Approve

Based on 4 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Geron.

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers